Sanofi Expects Strong Earnings Growth This Year, Plans $5.2 Billion Buyback
The pharmaceutical company forecasts business earnings per share growth at a low double-digit percentage and plans to launch a $5.2 billion share buyback.
Sanofi Plans €5 Billion Buyback, Sees Higher Profit Growth
Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots away from consumer health to focus on fast-growing drugs like its RSV shot.Earnings per share,
Sanofi Expected to Report Lower Sales, Profit; Size of Buyback in Focus -- Earnings Preview
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara Research consensus. Sanofi reported a business operating profit of 2.58 billion euros in the year-earlier period.
Sanofi targets mid to high single-digit sales growth in 2025 with €5B share buyback plan
Q4 guidance included expanded metrics for 2025, such as mid to high single-digit sales growth and low double-digit EPS growth, compared to a more cautious outlook in Q3. Management also introduced a €5 billion share buyback, reflecting increased confidence in financial flexibility.
Sanofi plans share buybacks, signals more deals post Opella sale
Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large stake in its consumer health unit.
Sanofi forecasts stronger profit growth, announces €5 billion stock buyback
Sanofi (EPA:SASY) (NASDAQ:SNY) announced on Thursday that it plans to repurchase €5 billion ($5.21 billion) worth of shares this year and may take a more active approach to acquisitions in the near term.
FiercePharma2d
Sanofi's RSV antibody Beyfortus, after smashing blockbuster sales threshold, still has room to grow in US: execs
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
FierceBiotech2d
Sanofi cuts programs tied to multibillion-dollar deals from pipeline
Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...
Kepler Capital Sticks to Its Hold Rating for Sanofi (SNYNF)
In a report released on January 30, David Evans from Kepler Capital maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price ...
Sanofi (NASDAQ:SNY) Upgraded to “Hold” at Deutsche Bank Aktiengesellschaft
Sanofi (NASDAQ:SNY – Get Free Report) was upgraded by stock analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a report released on Thursday, Marketbeat Ratings ...
BioSpace2d
Sanofi Earnings Driven by Dupixent, New RSV Vaccine as Hunt for Deals Continues
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
Sanofi: Positioned for Strong Growth with Conservative Guidance and Strategic Initiatives
Analyst Graham Parry of Bank of America Securities reiterated a Buy rating on Sanofi (SNYNF – Research Report), boosting the price target to ...
American Association of Individual Investors1d
Which Is a Better Investment, Sanofi or Zoetis Inc. Stock?
Learn more about whether Sanofi or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
GlobalData on MSN1d
Sanofi reports Q4 2024 increase in net income to $916m
Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...